Two drugs commonly prescribed to treat Type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or amputation, according to a new Northwestern Medicine study.
Dec 21, 2018
0
428
A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, ...
Mar 1, 2016
0
16
(HealthDay)—A proof-of-concept study will be able to examine the contribution of glycemic variability to outcomes of type 2 diabetes, according to a report published online June 11 in Diabetes Care.
Jun 25, 2015
0
5
Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously ...
Sep 12, 2014
0
0
(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online ...
Jun 17, 2016
0
3
(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes.
Nov 17, 2015
0
7
(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...
Dec 20, 2016
0
0
(HealthDay)—Lixisenatide and glulisine as add-on to basal insulin result in a reduction in glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, according to a study published online June 22 in Diabetes Care.
Jul 1, 2016
0
3
Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes. These revolutionary, ...
Jun 24, 2011
0
0
For youth with type 2 diabetes, dulaglutide is superior to placebo for reducing mean glycated hemoglobin level, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual ...
Jun 8, 2022
0
2
